Erschienen in:
19.07.2019 | Urology - Original Paper
Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer
verfasst von:
Keina Nozaki, Taketo Kawai, Tetsuya Fujimura, Hotaka Matsui, Taro Teshima, Takahiro Oshina, Atsuko Takahashi, Yusuke Sato, Daisuke Yamada, Takeshi Azuma, Masatoshi Hotta, Kazuhiko Nakajima, Hidetsugu Nakayama, Ryogo Minamimoto, Haruki Kume
Erschienen in:
International Urology and Nephrology
|
Ausgabe 10/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Carbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake.
Methods
We collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS).
Results
Seven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23–100%). Median PFS was 8.5 months (range, 2.8–25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases.
Conclusions
11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.